Mereo BioPharma Group plc (MREO)
After hours:
| Previous close | 3.0400 |
| Open | 3.0300 |
| Bid | 2.9700 x 400 |
| Ask | 3.0000 x 600 |
| Day's range | 2.8750 - 3.0300 |
| 52-week range | 0.9200 - 4.3600 |
| Volume | |
| Avg. volume | 1,016,451 |
| Market cap | 419.416M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings date | 29 Mar 2024 - 02 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.26 |
GlobeNewswireMereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. “2024 is off to an exciting start fo
ZacksMEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Compa
